At the Drug Safety Research Unit (DSRU), our aim is to achieve the highest possible scientific and ethical standards, by putting the interests of patients first and to work with integrity and fairness with all our partners.

Through our historical links with doctors in the NHS, the unit conducts studies in both primary and secondary care, many of which are risk management studies which are part of Risk Management Plans (RMPs) in the EU.

Our activities are principally concerned with pharmacovigilance, that is, the detection of side-effects associated with the use of marketed drugs. The DSRU undertakes all forms of research studies and evaluations of the safety of medicines.

We are an independent unit providing scientific excellence demonstrated through conducting studies, which have been used to support public health decisions and production of publications in international peer reviewed journals since 1980.

The DSRU makes significant, valuable contributions in the area of post marketing surveillance of pharmaceutical products. We have achieved both recognition and endorsement by regulatory authorities, healthcare professionals and the pharmaceutical industry worldwide.

Health Care

Life Sciences

Pharmaceutical

Research

Drug Safety Research Unit (DSRU)

Saad Shakir

Fiona S.

Liz Lynn

Samantha Lane

Debabrata Roy

The Research and Education team at the Drug Safety Research Unit (DSRU) is dedicated to advancing scientific knowledge and promoting high ethical standards in pharmacovigilance. They conduct comprehensive studies to evaluate the safety of marketed drugs and contribute to public health decisions through research. Additionally, the team develops and manages educational programs and training courses to disseminate knowledge and best practices in drug safety to healthcare professionals and industry partners.

Research and Education

Research and Education

About

Team members